TransMedics Group Inc (NAS:TMDX)
$ 59.82 -1.2 (-1.97%) Market Cap: 2.01 Bil Enterprise Value: 2.24 Bil PE Ratio: 63.64 PB Ratio: 9.56 GF Score: 70/100

Transmedics Group Inc Annual Shareholders Meeting Transcript

May 27, 2021 / 12:00PM GMT
Release Date Price: $26.26 (+1.51%)
Waleed H. Hassanein
TransMedics Group, Inc. - Founder, MD, CEO, President & Director

Good morning, and welcome to the 2021 Annual Meeting of Shareholders of TransMedics Group, Inc. I am Waleed Hassanein, President and Chief Executive Officer of the TransMedics Group.

As I've stated publicly, 2021 is setting up to be a potentially transformative year for our business. We are advancing rapidly towards 2 major regulatory decisions on our OCS Heart and OCS Liver indications. That will have significant commercial ramification on our business and will fundamentally alter our long-term growth strategy. Our ultimate goal remains that we end 2021 with 3 approved transplant market indications in the United States, and we remain confident that this goal is attainable. I'm excited about and confident in the future of TransMedics as we continue to transform the field of organ transplantation using our Organ Care System technology platform.

As always, we are grateful for our shareholders' support for our business. Once again, this year, we are hosting our annual meeting virtually. It is my

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot